Association of TOPMed/CHARGE fibrinogen PRS with PheCodes in MVP∗
| Trait information . | MVP EUR . | MVP AFR . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PheCode . | Disease category . | Description . | No. of cases/controls . | PRS (MEGA) . | PRS (EUR) . | No. of cases/controls . | PRS (MEGA) . | PRS (AFR) . | ||||
| OR . | P value . | OR . | P value . | OR . | P value . | OR . | P value . | |||||
| phe_452 | Circulatory system | Other venous embolism and thrombosis | 26 792/421 526 | 0.952 | 2.26E-15† | 0.952 | 1.35E-15† | 7585/111 531 | 0.977 | 5.25E-02 | 0.972 | 1.76E-02‡ |
| phe_452_2 | Circulatory system | Deep vein thrombosis | 14 944/438 829 | 0.941 | 9.78E-14† | 0.941 | 6.88E-14† | 4498/116 209 | 0.964 | 1.60E-02‡ | 0.962 | 1.00E-02§ |
| phe_274_1 | Endocrine or metabolic | Gout | 42 682/406 941 | 1.031 | 2.96E-09† | 1.032 | 1.82E-09† | 14 511/104 430 | 1.022 | 1.51E-02‡ | 1.012 | 1.98E-01 |
| phe_274 | Endocrine or metabolic | Gout and other crystal arthrop | 44 888/402 674 | 1.030 | 4.02E-09† | 1.031 | 2.57E-09† | 14 941/103 648 | 1.022 | 1.43E-02‡ | 1.012 | 1.92E-01 |
| phe_681 | Dermatologic | Superficial cellulitis and abscess | 74 338/335 942 | 0.979 | 1.38E-07† | 0.979 | 1.80E-07† | 19 580/88 222 | 0.989 | 1.51E-01 | 0.988 | 1.38E-01 |
| phe_1089 | Other | Acquired absence of limb | 5 466/454 009 | 0.940 | 3.54E-06† | 0.940 | 3.83E-06† | 1675/120 554 | 0.998 | 9.50E-01 | 1.010 | 6.93E-01 |
| phe_681_5 | Dermatologic | Cellulitis and abscess of leg, except foot | 20 789/421 257 | 0.970 | 1.37E-05† | 0.970 | 1.35E-05† | 3302/115 194 | 1.000 | 9.85E-01 | 1.004 | 8.38E-01 |
| phe_280 | Hematopoietic | Iron-deficiency anemias | 35 686/404 586 | 1.024 | 1.94E-05† | 1.024 | 3.20E-05† | 14 819/100 241 | 1.038 | 3.97E-05† | 1.034 | 1.71E-04§ |
| phe_707_2 | Dermatologic | Chronic ulcer of leg or foot | 18 477/432 947 | 0.969 | 2.00E-05† | 0.969 | 2.37E-05† | 4470/115 706 | 0.994 | 6.73E-01 | 0.993 | 6.54E-01 |
| phe_286_81 | Hematopoietic | Primary hypercoagulable state | 2 498/457 232 | 0.921 | 2.51E-05† | 0.920 | 2.03E-05† | 529/121 823 | 0.957 | 3.11E-01 | 0.947 | 2.07E-01 |
| phe_286_2 | Hematopoietic | Encounter for long-term (current) use of anticoagulants | 42 101/409 581 | 0.979 | 3.04E-05† | 0.978 | 2.00E-05† | 7617/112 768 | 0.963 | 1.49E-03§ | 0.960 | 5.44E-04§ |
| phe_286 | Hematopoietic | Coagulation defects | 12 517/436 641 | 0.963 | 3.30E-05† | 0.963 | 3.18E-05† | 2804/116 917 | 0.936 | 4.47E-04§ | 0.934 | 3.01E-04§ |
| phe_286_8 | Hematopoietic | Hypercoagulable state | 2 691/456 755 | 0.925 | 3.52E-05† | 0.925 | 3.18E-05† | 586/121 682 | 0.964 | 3.70E-01 | 0.952 | 2.35E-01 |
| Trait information . | MVP EUR . | MVP AFR . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PheCode . | Disease category . | Description . | No. of cases/controls . | PRS (MEGA) . | PRS (EUR) . | No. of cases/controls . | PRS (MEGA) . | PRS (AFR) . | ||||
| OR . | P value . | OR . | P value . | OR . | P value . | OR . | P value . | |||||
| phe_452 | Circulatory system | Other venous embolism and thrombosis | 26 792/421 526 | 0.952 | 2.26E-15† | 0.952 | 1.35E-15† | 7585/111 531 | 0.977 | 5.25E-02 | 0.972 | 1.76E-02‡ |
| phe_452_2 | Circulatory system | Deep vein thrombosis | 14 944/438 829 | 0.941 | 9.78E-14† | 0.941 | 6.88E-14† | 4498/116 209 | 0.964 | 1.60E-02‡ | 0.962 | 1.00E-02§ |
| phe_274_1 | Endocrine or metabolic | Gout | 42 682/406 941 | 1.031 | 2.96E-09† | 1.032 | 1.82E-09† | 14 511/104 430 | 1.022 | 1.51E-02‡ | 1.012 | 1.98E-01 |
| phe_274 | Endocrine or metabolic | Gout and other crystal arthrop | 44 888/402 674 | 1.030 | 4.02E-09† | 1.031 | 2.57E-09† | 14 941/103 648 | 1.022 | 1.43E-02‡ | 1.012 | 1.92E-01 |
| phe_681 | Dermatologic | Superficial cellulitis and abscess | 74 338/335 942 | 0.979 | 1.38E-07† | 0.979 | 1.80E-07† | 19 580/88 222 | 0.989 | 1.51E-01 | 0.988 | 1.38E-01 |
| phe_1089 | Other | Acquired absence of limb | 5 466/454 009 | 0.940 | 3.54E-06† | 0.940 | 3.83E-06† | 1675/120 554 | 0.998 | 9.50E-01 | 1.010 | 6.93E-01 |
| phe_681_5 | Dermatologic | Cellulitis and abscess of leg, except foot | 20 789/421 257 | 0.970 | 1.37E-05† | 0.970 | 1.35E-05† | 3302/115 194 | 1.000 | 9.85E-01 | 1.004 | 8.38E-01 |
| phe_280 | Hematopoietic | Iron-deficiency anemias | 35 686/404 586 | 1.024 | 1.94E-05† | 1.024 | 3.20E-05† | 14 819/100 241 | 1.038 | 3.97E-05† | 1.034 | 1.71E-04§ |
| phe_707_2 | Dermatologic | Chronic ulcer of leg or foot | 18 477/432 947 | 0.969 | 2.00E-05† | 0.969 | 2.37E-05† | 4470/115 706 | 0.994 | 6.73E-01 | 0.993 | 6.54E-01 |
| phe_286_81 | Hematopoietic | Primary hypercoagulable state | 2 498/457 232 | 0.921 | 2.51E-05† | 0.920 | 2.03E-05† | 529/121 823 | 0.957 | 3.11E-01 | 0.947 | 2.07E-01 |
| phe_286_2 | Hematopoietic | Encounter for long-term (current) use of anticoagulants | 42 101/409 581 | 0.979 | 3.04E-05† | 0.978 | 2.00E-05† | 7617/112 768 | 0.963 | 1.49E-03§ | 0.960 | 5.44E-04§ |
| phe_286 | Hematopoietic | Coagulation defects | 12 517/436 641 | 0.963 | 3.30E-05† | 0.963 | 3.18E-05† | 2804/116 917 | 0.936 | 4.47E-04§ | 0.934 | 3.01E-04§ |
| phe_286_8 | Hematopoietic | Hypercoagulable state | 2 691/456 755 | 0.925 | 3.52E-05† | 0.925 | 3.18E-05† | 586/121 682 | 0.964 | 3.70E-01 | 0.952 | 2.35E-01 |
OR, odds ratio per SD increase in the PRS.
∗Analyses were only run if there were >500 cases or controls for a specific PheCode. Bonferroni threshold was determine separately in each ancestry group. EUR had 1426 PheCodes analyzed with an estimated 965 independent traits; therefore, Bonferroni = 0.05/965 = 5.18E-05. AFR had 1061 PheCodes analyzed with an estimated 690 independent traits; therefore, Bonferroni = 0.05/690 = 7.25E-05.
P ≤ Bonferroni threshold.
01 ≤ P < Bonferroni.
05 ≤ P < .01.